Fagherazzi, Guy http://orcid.org/0000-0001-5033-5966
Aguayo, Gloria A. http://orcid.org/0000-0002-5625-1664
Zhang, Lu http://orcid.org/0000-0001-7141-6730
Hanaire, Hélène http://orcid.org/0000-0002-8794-8990
Picard, Sylvie http://orcid.org/0000-0003-0463-8063
Sablone, Laura http://orcid.org/0000-0002-8026-7826
Vergès, Bruno http://orcid.org/0000-0001-8957-629X
Hamamouche, Naïma http://orcid.org/0009-0008-3188-9814
Detournay, Bruno http://orcid.org/0000-0001-7843-4608
Joubert, Michael http://orcid.org/0000-0002-8731-7355
Delemer, Brigitte http://orcid.org/0000-0002-4320-2601
Guilhem, Isabelle
Vambergue, Anne http://orcid.org/0000-0003-4307-8695
Gourdy, Pierre http://orcid.org/0000-0002-5362-3813
Hadjadj, Samy http://orcid.org/0000-0001-7110-6994
Velayoudom, Fritz-Line http://orcid.org/0000-0003-4623-3777
Guerci, Bruno http://orcid.org/0000-0002-6211-464X
Larger, Etienne http://orcid.org/0000-0002-1017-1845
Jeandidier, Nathalie http://orcid.org/0000-0002-9730-5008
Gautier, Jean-François http://orcid.org/0000-0001-6458-2001
Renard, Eric http://orcid.org/0000-0002-3407-7263
Potier, Louis http://orcid.org/0000-0001-6268-7360
Benhamou, Pierre-Yves http://orcid.org/0000-0003-4378-0468
Sola, Agnès http://orcid.org/0000-0002-1091-897X
Bordier, Lyse http://orcid.org/0000-0002-9154-4841
Bismuth, Elise http://orcid.org/0000-0002-9503-9279
Prévost, Gaëtan http://orcid.org/0000-0001-9856-5859
Kessler, Laurence http://orcid.org/0000-0002-1769-5625
Cosson, Emmanuel http://orcid.org/0000-0002-8785-3385
Riveline, Jean-Pierre http://orcid.org/0000-0001-7991-0741
,
Article History
Received: 5 October 2023
Accepted: 8 April 2024
First Online: 23 May 2024
Acknowledgements
: We would like to express our deepest gratitude to the participants of the SFDT1 study for their valuable contribution. Their participation is instrumental in the progress of type 1 diabetes-related research. We thank the French Juvenile Diabetes Research Foundation for supporting the SFDT1 study (grant 3-SRA-2023-1347-S-B). Additionally, we thank the SFDT1 study group for their diligent efforts and dedication to the study. Their collective expertise and commitment have played a critical role in ensuring a high-quality standard for the SFDT1 data. We also want to acknowledge the substantial work of Sanoïa CRO in supporting the management and execution of the study. Their professional conduct and expertise have ensured the rigorous implementation of our study protocol. Special thanks go to M. Huet and M. Brulé for their exceptional contribution to the clinical operations of the SFDT1 study conduct. Their unwavering dedication has enriched our research and helped drive the study forward. We are sincerely grateful for the collaboration and dedication of all those involved, and we believe their invaluable contributions will continue to benefit future research in this field. The full list of active participants of the SFDT1 study group can be found here below:Jean-Pierre Riveline, Jean-Baptiste Julla, Tiphaine Vidal-Trécan, Vanessa Juddoo, Bruno Vergès, Sylvaine Clavel, Hermione Agopian, Emmanuel Cosson, Sopio Tatulashvili, Sylvie Picard, Fritz-Line Velayoudom, Alexana Prevot, Claude Gruel, Ingrid Cirederf, Charles Thivolet, Mélanie Gaudilliere, Sylvie Villar-Fimbel, Béatrice Mestre Filippini, Elise Bismuth, Hassina Benlarbi, Jacques Beltrand, Alix Besançon, Pierre-Yves Benhamou, Sanine Lablanche, Manon Jalbert, Louis Potier, Aurélie Carlier, Agnès Sola, Nathalie Jeandidier, Laurence Kessler, Marion Munch, Hélène Hanaire, Pierre Gourdy, Raquel Tirado, Vincent Melki, Sarah Pinto, Yves Reznik, Bleuenn Dreves, Michael Joubert, Anne Rod, Sophie Borot, Annie Clergeot, Nathalie Bendelac, Vincent Rigalleau, Amandine Ferriere, Alice Larroumet, Isabelle Guilhem, Christele Derrien, Agathe Guenego, Patricia Vaduva, Elsa Bleichner, Emeric Rageul, Margot De La Vergne De Cerval, Annabelle Esvant, Mathilde Fichet, Auey Durous, Laurent Meyer, Lyse Bordier, Cyril Garcia, Sika Nassouri, Mathilde Sollier, Bruno Guerci, Stéphanie Jellimann, Philip Böhme, Nicolas Scheyer, Mazen Soliman, Meliha Mahmutovic, Laura Mayer, Sylvia Franc, Alfred Penfornis, Coralie Amadou, Nicolas Chevalier, Anne-Gaëlle Decoux-Poullot, Stéphanie Palle Defille, Gaetan Prevost, Lucile Moreau Grange, Karine Durand, Florence Eas, Eric Renard, Anne Farret, Florence Galtier, Brigitte Delemer, Claire Carette, Alina Radu, Amel Ait Boudaoud Hansal, Samy Hadjadj, Pierre Morcel, Nadine Lucidarme, Igor Tauveron, Thomas Benichou, Sylvain Roumeau, Sarah Dallel, Mathilde Picard, Pierre-François Souchon, Anne Sophie Salmon-Musial, Aurelie Berot, Lucien Marchand, Cédric Luyton, Isabela Banu, Blandine Delenne, Anne Vambergue, Didier Gouet, Emmanuel Sonnet, Nathalie Roudaut, Anne Spiteri, Pierre Henri Ducluzeau, Kalliopi Bilariki, Rachel Reynaud, Emmanuelle Sokol, Camille Vatier, Bénédicte Fremy, Pascal Barat, Marc De Kerdanet, Brigitte Mignot, Laurence Salle, Caroline Sanz, Marie Mansilla, Paul Valenci, Pascale Massin.Some of the data were presented as an abstract at the European Diabetes Epidemiology Group Annual Meeting and at the Advanced Technologies & Treatments for Diabetes conference in 2023.
: Data used for this analysis are available for academic researchers on request submitted to the scientific committee of SFDT1: cohorte.sfdt1@gmail.com. Codes created for this analysis are available on request to the corresponding author: guy.fagherazzi@lih.lu.
: This work was made possible thanks to the institutional support from the Fondation Francophone pour la Recherche sur le Diabète (FFRD), the Société Francophone du Diabète (SFD) and the Luxembourg Institute of Health, as well as from the following partners: Aide aux Jeunes Diabétiques (AJD), Fédération Française des Diabétiques, Lilly, Abbott, Air Liquide Healthcare, Novo Nordisk, Sanofi, Insulet, Medtronic, Dexcom, Ypsomed, Lifescan and Sur les Pas de So. The study sponsors/funders were not involved in the design of the study; the collection, analysis and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.
: LB has performed consultancies and received honorarium from Eli Lilly, Boehringer Ingelheim, Novo Nordisk, Sanofi, AstraZeneca, Bayer, Servier, Pfizer, Abbott and MSD. MJ has performed clinical trials for and/or has provided advisory/speaking services for and/or has received research grants from Abbott, Air Liquide Healthcare, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Dexcom, Glooko, Lifescan, Eli Lilly, LVL, Medtronic, MSD, Nestle Home Care, Novo Nordisk, Orkyn, Roche Diabetes, Sanofi, Vitalaire and Voluntis. HH has performed clinical trials for and/or has provided advisory/speaking services for and/or has received research grants from Abbott, Air Liquide Healthcare, AstraZeneca, Insulet Isis, Lifescan, Lilly, Medtronic, MSD, Novo Nordisk, Sanofi and Vitalaire. P-YB has received speaker honoraria from Abbott, Eli Lilly, Novo Nordisk and Sanofi; is the chief medical officer for Diabeloop; and served on advisory board panels for Abbott, Dexcom, Insulet, LifeScan, Eli Lilly, Novo Nordisk and Sanofi. LP has provided advisory/speaking services for and/or has received research grants from Eli Lilly, Novo Nordisk, AstraZeneca, Bayer, Boehringer Ingelheim and Sanofi. EB has received speaker honoraria from Abbott, Eli Lilly, Novo Nordisk, Dexcom, Vitalaire, Orkyn and Dinnosanté; served on advisory board panels for Insulet, Eli Lilly, Medtronic and Novo Nordisk; and performed clinical trials for Eli Lilly, Vitalaire and ProventionBio. GF has provided advisory/speaking services for and/or has received research grants and/or speaker honoraria from MSD, MSDAvenir, Eli Lilly, Roche Diabetes Care, AstraZeneca, Danone Research, Diabeloop, Bristol Myers Squibb, L’Oréal R&D, Abbvie Pharmaceutical, Pfizer, Vitalaire and Akuity Care. J-PR is an advisory panel member for Sanofi, MSD, Eli Lilly, Novo Nordisk, AstraZeneca, Abbott, Dexcom, Alphadiab, Air Liquide Healthcare and Medtronic; and has received research funding from and provided research support to Abbott, Air Liquide Healthcare, Sanofi and Novo Nordisk. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: GF conceived the study. GAA and GF wrote the first draft. J-PR and EC are the co-principal investigators. GAA, GF, LZ, J-PR and EC had full access to the data in the study, verified the data and had full responsibility for the decision to submit and publish. GF, HH, SP, LS, BV, NH, B. Detournay, MJ, B. Delemer, IG, AV, PG, SH, F-LV, BG, EL, NJ, J-FG, ER, LP, P-YB, AS, LB, EB, GP, LK, EC and J-PR contributed to protocol development and study design. NH collected the data. GAA and LZ performed the statistical analyses. GAA, GF, J-PR and EC wrote the statistical analysis plan (SAP). All authors read the SAP, critically revised it for important intellectual content and approved the final version. All authors read the manuscript, critically revised it for academic content and approved the final version. GF is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.